RET (Y806H)

RET · Variant type: point · HGVS: p.Y806H

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pralsetinib	100.0%	0.0%	93.43
2	Tivozanib	99.9%	0.1%	92.42
3	Selpercatinib	99.9%	0.1%	96.72
4	Fedratinib	99.0%	1.0%	96.21
5	Entrectinib	98.4%	1.6%	93.69
6	Alpelisib	98.4%	1.6%	97.22
7	Tenalisib	97.8%	2.2%	97.98
8	Lenvatinib	96.7%	3.3%	97.74
9	Apatinib	96.6%	3.4%	97.73
10	Ponatinib	96.6%	3.4%	78.23
11	Nintedanib	96.3%	3.7%	90.23
12	Alectinib	96.0%	4.0%	95.49
13	Regorafenib	95.1%	4.9%	95.99
14	Sorafenib	93.9%	6.1%	96.72
15	Gilteritinib	93.3%	6.7%	88.97
16	Ripretinib	93.1%	6.9%	92.95
17	Cabozantinib	92.5%	7.5%	92.73
18	Sunitinib	91.7%	8.3%	91.73
19	Futibatinib	90.0%	10.0%	98.48
20	Erdafitinib	87.9%	12.1%	95.71
21	Brigatinib	86.1%	13.9%	82.96
22	Quizartinib	84.1%	15.9%	99.50
23	Repotrectinib	78.6%	21.4%	84.21
24	Vandetanib	62.7%	37.3%	95.74
25	Avapritinib	62.2%	37.8%	97.73

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pralsetinib	100.0%	100.0%	+0.0%
Tivozanib	99.9%	99.7%	+0.2%
Selpercatinib	99.9%	100.0%	-0.1%
Fedratinib	99.0%	99.9%	-0.9%
Entrectinib	98.4%	99.6%	-1.2%
Alpelisib	98.4%	99.6%	-1.3%
Tenalisib	97.8%	98.5%	-0.7%
Lenvatinib	96.7%	98.8%	-2.2%
Apatinib	96.6%	—	—
Ponatinib	96.6%	100.0%	-3.4%
Nintedanib	96.3%	100.0%	-3.7%
Alectinib	96.0%	97.8%	-1.8%
Regorafenib	95.1%	98.7%	-3.6%
Sorafenib	93.9%	94.0%	-0.1%
Gilteritinib	93.3%	100.0%	-6.7%
Ripretinib	93.1%	—	—
Cabozantinib	92.5%	97.5%	-5.1%
Sunitinib	91.7%	97.2%	-5.5%
Futibatinib	90.0%	97.7%	-7.7%
Erdafitinib	87.9%	94.7%	-6.8%
Brigatinib	86.1%	94.9%	-8.8%
Quizartinib	84.1%	—	—
Repotrectinib	78.6%	—	—
Vandetanib	62.7%	98.6%	-35.9%
Avapritinib	62.2%	—	—

Cancer	Organ	Source
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.3ms